meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
5
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population
5
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant
1
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative
1
mNSCLC - L2 - PDL1 positive
7
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population
1
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population
1
squamous - mNSCLC - L2 - PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab plus osimertinib
versus all
vs gene alteration target therapy
vs EGFR gene alteration
vs osimertinib
All patients
Age < 65y (younger)
Age > 65y
Asian type
EGFR mutation Ex19del
EGFR mutation L858R
Gender, female
Gender, male
metastasis (brain) NO
metastasis (brain) YES
smoker (current or former)
smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DCR
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
DCR
mNSCLC - L2 - EGFR mutant
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L2 - EGFR mutant
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open